---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011509"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:09:21.073158+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma reports 2023 net loss $22.9M; cash runway only through Q3 2024

## Summary
- Revenue fell to $1.1M from $3.2M; net loss per share $0.11 vs $0.10 prior year.
- Cash and equivalents $13.8M at Dec 31, 2023, down from $28.8M; company sees funding only through Q3 2024.
- FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis.
- Compassionate use program: 19 patients enrolled; most with renal recovery after switching from AmBisome; 8 completed with complete resolution.
- Preclinical LNC-docetaxel shows comparable efficacy to IV-docetaxel with no weight loss in mice.

## SEC filing metadata
- accession: 0001493152-24-011509
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/0001493152-24-011509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011509
- JSON: https://secwatch.observer/filing/0001493152-24-011509.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011509.txt

## Key facts
- Earnings Releases
  Matinas BioPharma Holdings, Inc. reported financial results for for the year and quarter ended December 31, 2023.
  - Period: for the year and quarter ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315224011509/0001493152-24-011509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.